GlobeNewswire BiotechnologyCodex · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 20:00:00·⟳ 抓取 20:01:53·⚡ 决策 09-01 22:29:47 +2h27m·56.2 天前
Voyager Therapeutics将参加多场投资者会议，未披露业务或财务增量
完整正文显示为例行会议参会公告，没有新增业务、临床、监管、财务或资本结构信息，无法形成正期望交易。
📄 原文GlobeNewswire Biotechnology↗ 原文
Voyager to Present at Upcoming Investor Conferences
LEXINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company…
不做 Voyager Therapeutics, Inc.（VYGR.US）
例行投资者会议公告，无新增临床、监管、合作、融资或财务信息，事件增量不足以交易。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
事件事实是Voyager Therapeutics公布未来数场投资者会议及webcast时间；该类日程公告本身不改变公司管线成功率、收入、现金流或估值锚，也没有新披露数据或交易条款，因此即使标的可交易，也缺少方向明确的事件增量。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 low ↗
主要风险
- 后续会议中若临时披露临床、合作或财务新信息，需要作为新事件重新评估。
先例如何影响了这次决策
对本次决策的影响:确认不因会议日程本身建立仓位。
方向:例行投资者会议日程公告缺少可测的基本面方向，先例研究不会改变不交易结论。
涨幅量级:无可用于校准幅度的高相似基本面事件。
形态:未做幅度外推；本事件不是临床、合作、融资或业绩披露。
原文全文
展开原文 · 2,338 字
LEXINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences:
Wells Fargo 21st Annual Healthcare Conference:
Fireside chat at 3:45 p.m. ET on Tuesday, September 8, 2026, in Boston, MA.
2026 Cantor Global Healthcare Conference:
Fireside chat at 8:35 a.m. ET on Friday, September 11, 2026, in New York, NY.
Morgan Stanley 24th Annual Global Healthcare Conference:
Fireside chat at 10:45 a.m. ET on Monday, September 14, 2026, in New York, NY.
Baird’s 2026 Global Healthcare Conference:
Fireside chat at 7:55 a.m. ET on Tuesday, September 15, 2026, in New York, NY.
H.C. Wainwright 28th Annual Global Investment Conference:
Fireside chat at 2:30 p.m. ET on Tuesday, September 15, 2026, in New York, NY.
A webcast of the Wells Fargo fireside chat will be available and may be accessed from the Investors section of Voyager’s website at
ir.voyagertherapeutics.com
. A replay of the webcast will be archived on the company’s website for at least 30 days.
About Voyager Therapeutics
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit
http://www.voyagertherapeutics.com
.
Voyager Therapeutics
®
is a registered trademark, and TRACER™
and Voyager NeuroShuttle™ are trademarks, of Voyager Therapeutics, Inc.
Contacts
Company and Investors: Trista Morrison, NACD.DC,
tmorrison@vygr.com
Media: Lisa Guiterman,
voyagerpr@scientpr.com
Wells Fargo 21st Annual Healthcare Conference:
Fireside chat at 3:45 p.m. ET on Tuesday, September 8, 2026, in Boston, MA.
2026 Cantor Global Healthcare Conference:
Fireside chat at 8:35 a.m. ET on Friday, September 11, 2026, in New York, NY.
Morgan Stanley 24th Annual Global Healthcare Conference:
Fireside chat at 10:45 a.m. ET on Monday, September 14, 2026, in New York, NY.
Baird’s 2026 Global Healthcare Conference:
Fireside chat at 7:55 a.m. ET on Tuesday, September 15, 2026, in New York, NY.
H.C. Wainwright 28th Annual Global Investment Conference:
Fireside chat at 2:30 p.m. ET on Tuesday, September 15, 2026, in New York, NY.
A webcast of the Wells Fargo fireside chat will be available and may be accessed from the Investors section of Voyager’s website at
ir.voyagertherapeutics.com
. A replay of the webcast will be archived on the company’s website for at least 30 days.
About Voyager Therapeutics
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit
http://www.voyagertherapeutics.com
.
Voyager Therapeutics
®
is a registered trademark, and TRACER™
and Voyager NeuroShuttle™ are trademarks, of Voyager Therapeutics, Inc.
Contacts
Company and Investors: Trista Morrison, NACD.DC,
tmorrison@vygr.com
Media: Lisa Guiterman,
voyagerpr@scientpr.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。